Novo Nordisk: Bryan Garnier remains 'neutral'

(CercleFinance.com) - An analyst at Bryan Garnier today says that he is maintaining his “neutral” rating on the Novo Nordisk stock, against a backdrop of reassuring clinical trial results relative to competition.


“Novo Nordisk (...) presented data assessing most of the company's new medicines relative to their direct competitors with these systematically beating rivals to confirm best-in-class status.”

Although this data does not guarantee a commercial success, the broker notes, it still constitutes a good basis for the next few months. The broker is therefore maintaining its fair value for the share at 330 Danish kronor.


Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.